Success Metrics

Clinical Success Rate
88.4%

Based on 122 completed trials

Completion Rate
88%(122/138)
Active Trials
31(16%)
Results Posted
52%(63 trials)
Terminated
16(8%)

Phase Distribution

Ph phase_2
32
16%
Ph phase_1
21
11%
Ph phase_4
41
21%
Ph phase_3
44
22%
Ph not_applicable
10
5%
Ph early_phase_1
1
1%

Phase Distribution

22

Early Stage

32

Mid Stage

85

Late Stage

Phase Distribution149 total trials
Early Phase 1First-in-human
1(0.7%)
Phase 1Safety & dosage
21(14.1%)
Phase 2Efficacy & side effects
32(21.5%)
Phase 3Large-scale testing
44(29.5%)
Phase 4Post-market surveillance
41(27.5%)
N/ANon-phased studies
10(6.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.1%

122 of 145 finished

Non-Completion Rate

15.9%

23 ended early

Currently Active

31

trials recruiting

Total Trials

200

all time

Status Distribution
Active(39)
Completed(122)
Terminated(23)
Other(16)

Detailed Status

Completed122
Recruiting26
unknown16
Terminated16
Not yet recruiting8
Withdrawn7

Development Timeline

Analytics

Development Status

Total Trials
200
Active
31
Success Rate
88.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (0.7%)
Phase 121 (14.1%)
Phase 232 (21.5%)
Phase 344 (29.5%)
Phase 441 (27.5%)
N/A10 (6.7%)

Trials by Status

active_not_recruiting53%
unknown168%
completed12261%
not_yet_recruiting84%
withdrawn74%
recruiting2613%
terminated168%

Recent Activity

31 active trials
Showing 5 of 200
active_not_recruitingphase_4

Effect of Two Weeks of Low-Dose Apixaban on Platelet Reactivity in Patients With Stable Coronary Artery Disease on Dual Antiplatelet Therapy (Aspirin and Clopidogrel)

NCT07853612
recruitingphase_4

COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation

NCT04642430
not_yet_recruitingphase_4

Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism

NCT07852637
recruitingphase_3

Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment

NCT07160686
recruitingphase_3

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

NCT07626411
View all 200 trials

Clinical Trials (200)

Showing 20 of 200 trialsScroll for more
NCT07853612Phase 4

Effect of Two Weeks of Low-Dose Apixaban on Platelet Reactivity in Patients With Stable Coronary Artery Disease on Dual Antiplatelet Therapy (Aspirin and Clopidogrel)

Active Not Recruiting
NCT04642430Phase 4

COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation

Recruiting
NCT07852637Phase 4

Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism

Not Yet Recruiting
NCT07160686Phase 3

Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment

Recruiting
NCT07626411Phase 3

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

Recruiting
NCT07175428Phase 2

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

Recruiting
NCT07493304Phase 3

Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

Recruiting
NCT07015905Phase 3

REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

Recruiting
NCT05757869Phase 3

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

Active Not Recruiting
NCT02559856Phase 4

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban: The Pilot Study

Completed
NCT06650501Phase 4

Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia

Recruiting
NCT06953726Phase 4

Comparing the Safety and Efficacy of Apixaban and Rivaroxaban

Recruiting
NCT06474182Not Applicable

Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma

Recruiting
NCT05484557Not Applicable

Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury

Recruiting
NCT07471139Phase 3

SWITCH: Apixaban vs Vitamin K in HM3

Not Yet Recruiting
NCT05773222

Efficacy and Safety of Apixaban in Korean Frail Atrial Fibrillation Patient

Completed
NCT07753200Phase 4

Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease

Recruiting
NCT07747948

Population Pharmacokinetics of Apixaban in Asian Patients With Atrial Fibrillation

Not Yet Recruiting
NCT04618913

Anticoagulation in Patients With Venous Thromboembolism and Cancer

Completed
NCT07716332Not Applicable

Apixaban Versus Enoxaparin for Postpartum Venous Thromboembolism Prophylaxis

Not Yet Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
200